Table 6.

Impact of SARS-Cov-2 positivity on outcomes on group 2

Outcome	SARS-Cov-2 negative N = 81 (94.2)	SARS-Cov-2 positive N = 5 (5.8)	p-value	Crude OR (95% CI), p-value
Intra-operative complications, n (%)	0 (0.0)	1 (20.0)	0.06	n.a.
Post-operative morbidity, n (%)	19 (24.7)	0 (0.0)	0.58	n.a.
Dindo-Clavien 0–2, n (%)	67 (87.0)	5 (100.0)	1.0	n.a.
Dindo-Clavien 3–4, n (%)	8 (10.4)	0 (0.0)
Dindo-Clavien 5, n (%)	2 (2.6)	0 (0.0)
Blood transfusions, n (%)	6 (7.8)	1 (20.0)	0.37	2.96 (0.28–30.85), p = 0.37
30-day mortality, n (%)	3 (3.9)	0 (0.0)	1.0	n.a.
ICU admissions, n (%)	2 (2.6)	1 (20.0)	0.17	9.37 (0.69–126.56), p = 0.09
Declared Delayed access > 48 h, n (%)	9 (11.8)	1 (20.0)	0.49	1.29 (0.13–12.48), p = 0.82
Post-operative LOS, median (q1–q3)	4 (2–9)	9 (8-10)	0.11	n.a.

CI confidence interval, ICU intensive care unit, LOS length of stay, OR odds ratio, q1 first quartile, q3 third quartile